Response to drug treatment in newly diagnosed epilepsy: a pilot study of 1H NMR- and MS-based metabonomic analysis

G. Sills, M. Alzweiri, J. Leach, M. Brodie, C. Robertson, D.G. Watson, J.A. Parkinson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Understanding the biological basis of drug resistance and developing techniques which facilitate prediction of outcome have the potential to revolutionise the pharmacotherapy of epilepsy.We have performed a pilot study of metabonomic analysis using nuclear magnetic resonance(NMR) spectroscopy and mass spectrometry (MS) in an effort to identify metabolic biomarkers of response to antiepileptic drug treatment. Pretreatment serum samples were obtained from 125 patients with newly diagnosed epilepsy who were taking part in a randomized monotherapy trial. Outcome (responder, nonresponder) was assessed at 6 weeks, 6 months, and 12 months after starting treatment. Serum samples were subject to investigation by both NMR and MS and the resulting data interrogated by principal component analysis. There was no clear distinction in the metabolic profile, acquired by either NMR or MS, of responders and nonresponders to AED treatment at any of the three clinical end points investigated, suggesting that pretreatment serum samples do not contain any prominent biomarkers of responsiveness to initial treatment in new-onset epilepsy. Metabonomic analysis is undoubtedly applicable to the search for biological predictors of response to drug treatment in epilepsy, but future studies should employ larger patient cohorts, more discriminatory analyses, and a less equivocal clinical phenotype.
LanguageEnglish
Pages189-195
Number of pages6
JournalEpilepsy Research
Volume88
Issue number2-3
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Metabolomics
Epilepsy
Mass Spectrometry
Magnetic Resonance Spectroscopy
Pharmaceutical Preparations
Biomarkers
Serum
Therapeutics
Metabolome
Principal Component Analysis
Drug Resistance
Anticonvulsants
Phenotype
Drug Therapy

Keywords

  • epilepsy
  • drug treatment
  • drug resistance
  • pharmacotherapy
  • metabonomic analysis
  • antiepileptic drugs
  • response to treatment
  • metabonomics
  • nuclear magnetic resonance spectroscopy
  • mass spectrometry
  • principal components analysis

Cite this

@article{59312064284b401a88499b3ea2b9f8c5,
title = "Response to drug treatment in newly diagnosed epilepsy: a pilot study of 1H NMR- and MS-based metabonomic analysis",
abstract = "Understanding the biological basis of drug resistance and developing techniques which facilitate prediction of outcome have the potential to revolutionise the pharmacotherapy of epilepsy.We have performed a pilot study of metabonomic analysis using nuclear magnetic resonance(NMR) spectroscopy and mass spectrometry (MS) in an effort to identify metabolic biomarkers of response to antiepileptic drug treatment. Pretreatment serum samples were obtained from 125 patients with newly diagnosed epilepsy who were taking part in a randomized monotherapy trial. Outcome (responder, nonresponder) was assessed at 6 weeks, 6 months, and 12 months after starting treatment. Serum samples were subject to investigation by both NMR and MS and the resulting data interrogated by principal component analysis. There was no clear distinction in the metabolic profile, acquired by either NMR or MS, of responders and nonresponders to AED treatment at any of the three clinical end points investigated, suggesting that pretreatment serum samples do not contain any prominent biomarkers of responsiveness to initial treatment in new-onset epilepsy. Metabonomic analysis is undoubtedly applicable to the search for biological predictors of response to drug treatment in epilepsy, but future studies should employ larger patient cohorts, more discriminatory analyses, and a less equivocal clinical phenotype.",
keywords = "epilepsy, drug treatment, drug resistance, pharmacotherapy, metabonomic analysis, antiepileptic drugs, response to treatment, metabonomics, nuclear magnetic resonance spectroscopy, mass spectrometry, principal components analysis",
author = "G. Sills and M. Alzweiri and J. Leach and M. Brodie and C. Robertson and D.G. Watson and J.A. Parkinson",
year = "2010",
month = "2",
doi = "10.1016/j.eplepsyres.2009.11.005",
language = "English",
volume = "88",
pages = "189--195",
journal = "Epilepsy Research",
issn = "0920-1211",
number = "2-3",

}

Response to drug treatment in newly diagnosed epilepsy: a pilot study of 1H NMR- and MS-based metabonomic analysis. / Sills, G.; Alzweiri, M.; Leach, J.; Brodie, M.; Robertson, C.; Watson, D.G.; Parkinson, J.A.

In: Epilepsy Research, Vol. 88, No. 2-3, 02.2010, p. 189-195.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Response to drug treatment in newly diagnosed epilepsy: a pilot study of 1H NMR- and MS-based metabonomic analysis

AU - Sills, G.

AU - Alzweiri, M.

AU - Leach, J.

AU - Brodie, M.

AU - Robertson, C.

AU - Watson, D.G.

AU - Parkinson, J.A.

PY - 2010/2

Y1 - 2010/2

N2 - Understanding the biological basis of drug resistance and developing techniques which facilitate prediction of outcome have the potential to revolutionise the pharmacotherapy of epilepsy.We have performed a pilot study of metabonomic analysis using nuclear magnetic resonance(NMR) spectroscopy and mass spectrometry (MS) in an effort to identify metabolic biomarkers of response to antiepileptic drug treatment. Pretreatment serum samples were obtained from 125 patients with newly diagnosed epilepsy who were taking part in a randomized monotherapy trial. Outcome (responder, nonresponder) was assessed at 6 weeks, 6 months, and 12 months after starting treatment. Serum samples were subject to investigation by both NMR and MS and the resulting data interrogated by principal component analysis. There was no clear distinction in the metabolic profile, acquired by either NMR or MS, of responders and nonresponders to AED treatment at any of the three clinical end points investigated, suggesting that pretreatment serum samples do not contain any prominent biomarkers of responsiveness to initial treatment in new-onset epilepsy. Metabonomic analysis is undoubtedly applicable to the search for biological predictors of response to drug treatment in epilepsy, but future studies should employ larger patient cohorts, more discriminatory analyses, and a less equivocal clinical phenotype.

AB - Understanding the biological basis of drug resistance and developing techniques which facilitate prediction of outcome have the potential to revolutionise the pharmacotherapy of epilepsy.We have performed a pilot study of metabonomic analysis using nuclear magnetic resonance(NMR) spectroscopy and mass spectrometry (MS) in an effort to identify metabolic biomarkers of response to antiepileptic drug treatment. Pretreatment serum samples were obtained from 125 patients with newly diagnosed epilepsy who were taking part in a randomized monotherapy trial. Outcome (responder, nonresponder) was assessed at 6 weeks, 6 months, and 12 months after starting treatment. Serum samples were subject to investigation by both NMR and MS and the resulting data interrogated by principal component analysis. There was no clear distinction in the metabolic profile, acquired by either NMR or MS, of responders and nonresponders to AED treatment at any of the three clinical end points investigated, suggesting that pretreatment serum samples do not contain any prominent biomarkers of responsiveness to initial treatment in new-onset epilepsy. Metabonomic analysis is undoubtedly applicable to the search for biological predictors of response to drug treatment in epilepsy, but future studies should employ larger patient cohorts, more discriminatory analyses, and a less equivocal clinical phenotype.

KW - epilepsy

KW - drug treatment

KW - drug resistance

KW - pharmacotherapy

KW - metabonomic analysis

KW - antiepileptic drugs

KW - response to treatment

KW - metabonomics

KW - nuclear magnetic resonance spectroscopy

KW - mass spectrometry

KW - principal components analysis

UR - http://www.scopus.com/inward/record.url?scp=75849136402&partnerID=8YFLogxK

UR - http://dx.doi.org/10.1016/j.eplepsyres.2009.11.005

U2 - 10.1016/j.eplepsyres.2009.11.005

DO - 10.1016/j.eplepsyres.2009.11.005

M3 - Article

VL - 88

SP - 189

EP - 195

JO - Epilepsy Research

T2 - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 2-3

ER -